Dexcom Raises Another Billion, But Why?
The company’s cash balance at the end of last quarter was more than enough to weather most storms – so why has Dexcom raised more money?
You may also be interested in...
News We’re Watching: Medtronic To Buy EOFLow, Neuralink Cleared For Human Trials, NICE Backs Genetic Tests
This week, Medtronic said it would pay $738m for insulin patch firm EOFlow; Neuralink got an FDA OK for first-in-human trials; and UK agency NICE backed genetic tests for stroke patients and digital therapeutics for mental health conditions.
Medtronic’s 780G – Finally! – Gets FDA Approval
Earlier than expected, but still after a more than three year wait, the company has obtained FDA approval for its flagship insulin delivery system.
Dexcom Touts G7 As ‘The Most Accurate CGM’ As It Prepares For US Launch
The US FDA has granted authorization to Dexcom to market its G7 continuous glucose monitor, which the company will launch in the next couple of months.